Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Osteopontin (Spp1)

  • Swapnil Bawage
  • Shannon E. Weeks
  • Lalita A. Shevde
  • Rajeev S. Samant
Reference work entry
First Online:
DOI: https://doi.org/10.1007/978-3-319-67199-4_101771
How to cite

Synonyms

 Bone sialoprotein 1;  BNSP;  BSPI;  Early T-lymphocyte activation 1;  ETA-1;  Nephropontin;  OPN;  Osteopontin;  Osteopontin-C;  Osteopontin-D;  Osteopontin/immunoglobulin alpha 1 heavy chain constant region fusion protein;  PSEC0156;  SPP-1;  Secreted phosphoprotein 1;  Secreted phosphoprotein 1 (osteopontin, bone sialoprotein I, early T-lymphocyte activation 1);  SPP1;  SPP1/CALPHA1 fusion;  Urinary stone protein;  Uropontin

Historical Background

The protein product of gene Spp1 is known by many names; however, osteopontin (OPN) is the most widely used and preferred. Osteopontin was first identified in osteoblasts and is primarily known for its role in bone mineralization, hence derives the name “osteo” for bone and pontin from “pons”- bridge in Latin. Orthologous gene analysis of Spp1 gene indicates that it is found in 39 eukaryotic genera. In humans, OPN is expressed in many organs and plays an important role in many cellular, physiological, immunological, and...

This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

NIH R01CA194048 grant to R.S.S.

References

  1. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF. Pre- and post-translational regulation of osteopontin in cancer. J of Cell Commun Signal. 2011;5:111–22. doi:10.1007/s12079-011-0130-6.CrossRefGoogle Scholar
  2. Beausoleil MS, Schulze EB, Goodale D, Postenka CO, Allan AL. Deletion of the thrombin cleavage domain of osteopontin mediates breast cancer cell adhesion, proteolytic activity, tumorgenicity, and metastasis. BMC Cancer. 2011;11. doi:10.1186/1471-2407-11-25.Google Scholar
  3. Bhattacharya SD, Mi Z, Kim VM, Guo H, Talbot LJ, Kuo PC. Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model. Ann Surg. 2012;255:319–25. doi:10.1097/SLA.0b013e31823e3a1c.CrossRefPubMedPubMedCentralGoogle Scholar
  4. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–7. doi:10.1038/nature01322.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Das S, Samant RS, Shevde LA. Nonclassical activation of Hedgehog signaling enhances multidrug resistance and makes cancer cells refractory to smoothened-targeting Hedgehog inhibition. J Biol Chem. 2013;288:11824–33. doi:10.1074/jbc.M112.432302.CrossRefPubMedPubMedCentralGoogle Scholar
  6. Denhardt DT, Noda M, O’Regan AW, Pavlin D, Berman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Investig. 2001;107:1055–61. doi:10.1172/jci12980.CrossRefPubMedPubMedCentralGoogle Scholar
  7. Fisher LW. DMP1 and DSPP: evidence for duplication and convergent evolution of two SIBLING proteins. Cells Tissues Organs. 2011;194:113–8. doi:10.1159/000324254.CrossRefPubMedPubMedCentralGoogle Scholar
  8. Florea A-M, Büsselberg D. Breast cancer and possible mechanisms of therapy resistance. J Local Global Health. 2013;2. doi:10.5339/jlghs.2013.2.Google Scholar
  9. Franzen A, Heinegard D. Isolation and characterization of two sialoproteins present only in bone calcified matrix. Biochem J. 1985;232:715–24.PubMedPubMedCentralCrossRefGoogle Scholar
  10. Heerboth S, Housman G, Leary M, Longacre M, Byler S, Lapinska K, et al. EMT and tumor metastasis. Clin Transl Med. 2015;4. doi:10.1186/s40169-015-0048-3.Google Scholar
  11. Ibrahim T, Leong I, Sanchez-Sweatman O, Khokha R, Sodek J, Tenenbaum HC, et al. Expression of bone sialoprotein and osteopontin in breast cancer bone metastases. Clin Exp Metastasis. 2000;18:253–60.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Inoue M, Shinohara ML. Intracellular osteopontin (iOPN) and immunity. Immunol Res. 2011;49:160–72. doi:10.1007/s12026-010-8179-5.CrossRefPubMedPubMedCentralGoogle Scholar
  13. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Investig. 2009;119:1420–8. doi:10.1172/jci39104.CrossRefPubMedPubMedCentralGoogle Scholar
  14. Kariya Y, Kanno M, Matsumoto-Morita K, Konno M, Yamaguchi Y, Hashimoto Y. OsteopontinO-glycosylation contributes to its phosphorylation and cell-adhesion properties. Biochem J. 2014;463:93–102. doi:10.1042/bj20140060.CrossRefPubMedPubMedCentralGoogle Scholar
  15. Katagiri YU, Murakami M, Mori K, Iizuka J, Hara T, Tanaka K, et al. Non-RGD domains of osteopontin promote cell adhesion without involving alpha v integrins. J Cell Biochem. 1996;62:123–31. doi:10.1002/(SICI)1097-4644(199607)62:1<123::AID-JCB13>3.0.CO;2-O.CrossRefPubMedPubMedCentralGoogle Scholar
  16. Kothari A, Arffa M, Chang V, Blackwell R, Syn W-K, Zhang J, et al. Osteopontin – a master regulator of epithelial-mesenchymal transition. J Clin Med. 2016;5:39. doi:10.3390/jcm5040039.CrossRefPubMedCentralGoogle Scholar
  17. Kurzbach D, Platzer G, Schwarz TC, Henen MA, Konrat R, Hinderberger D. Cooperative unfolding of compact conformations of the intrinsically disordered protein osteopontin. Biochemistry. 2013;52:5167–75. doi:10.1021/bi400502c.CrossRefPubMedPubMedCentralGoogle Scholar
  18. Kyprianou N, Huang J, Pan C, Hu H, Zheng S, Ding L. Osteopontin-enhanced hepatic metastasis of colorectal cancer cells. PLoS One. 2012;7:e47901. doi:10.1371/journal.pone.0047901.CrossRefGoogle Scholar
  19. Larue L, Bellacosa A. Epithelial–mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 2005;24:7443–54. doi:10.1038/sj.onc.1209091.CrossRefPubMedPubMedCentralGoogle Scholar
  20. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res. 1994;74:214–24.PubMedPubMedCentralCrossRefGoogle Scholar
  21. Luo S-D, Chen Y-J, Liu C-T, Rau K-M, Chen Y-C, Tsai H-T, et al. Osteopontin involves cisplatin resistance and poor prognosis in oral squamous cell carcinoma. Biomed Res Int. 2015;2015:1–13. doi:10.1155/2015/508587.CrossRefGoogle Scholar
  22. Machado JP, Johnson WE, O’Brien SJ, Vasconcelos V, Antunes A. Adaptive evolution of the matrix extracellular phosphoglycoprotein in mammals. BMC Evol Biol. 2011;11:342. doi:10.1186/1471-2148-11-342.CrossRefPubMedPubMedCentralGoogle Scholar
  23. Mason CK, McFarlane S, Johnston PG, Crowe P, Erwin PJ, Domostoj MM, et al. Agelastatin A: a novel inhibitor of osteopontin-mediated adhesion, invasion, and colony formation. Mol Cancer Ther. 2008;7:548–58. doi:10.1158/1535-7163.mct-07-2251.CrossRefPubMedPubMedCentralGoogle Scholar
  24. Mazzali M, Kipari T, Ophascharoensuk V, Wesson JA, Johnson R, Hughes J. Osteopontin – a molecule for all seasons. QJM: Mon J Assoc Physicians. 2002;95:3–13.CrossRefGoogle Scholar
  25. Mi Z, Guo H, Russell MB, Liu Y, Sullenger BA, Kuo PC. RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells. Mol Ther. 2008;17:153–61. doi:10.1038/mt.2008.235.CrossRefPubMedPubMedCentralGoogle Scholar
  26. Mi Z, Guo H, Kuo PC. Identification of osteopontin-dependent signaling pathways in a mouse model of human breast cancer. BMC Res Notes. 2009;2:119. doi:10.1186/1756-0500-2-119.CrossRefPubMedPubMedCentralGoogle Scholar
  27. Mitra A, Menezes ME, Pannell LK, Mulekar MS, Honkanen RE, Shevde LA, et al. DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3beta to downregulate beta-catenin transcription target, osteopontin. Oncogene. 2012;31:4472–83. doi:10.1038/onc.2011.623.CrossRefPubMedPubMedCentralGoogle Scholar
  28. Nemir M, Bhattacharyya D, Li X, Singh K, Mukherjee AB, Mukherjee BB. Targeted inhibition of osteopontin expression in the mammary gland causes abnormal morphogenesis and lactation deficiency. J Biol Chem. 2000;275:969–76.CrossRefGoogle Scholar
  29. Ng L, Wan T, Chow A, Iyer D, Man J, Chen G, et al. Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer. Stem Cells Int. 2015;2015:1–8. doi:10.1155/2015/247892.CrossRefGoogle Scholar
  30. Oldberg A, Franzen A, Heinegard D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A. 1986;83:8819–23.PubMedPubMedCentralCrossRefGoogle Scholar
  31. Prince CW, Oosawa T, Butler WT, Tomana M, Bhown AS, Bhown M, et al. Isolation, characterization, and biosynthesis of a phosphorylated glycoprotein from rat bone. J Biol Chem. 1987;262:2900–7.PubMedPubMedCentralGoogle Scholar
  32. Sangaletti S, Tripodo C, Sandri S, Torselli I, Vitali C, Ratti C, et al. Osteopontin shapes immunosuppression in the metastatic Niche. Cancer Res. 2014;74:4706–19. doi:10.1158/0008-5472.can-13-3334.CrossRefPubMedPubMedCentralGoogle Scholar
  33. Schulze EB, Hedley BD, Goodale D, Postenka CO, Al-Katib W, Tuck AB, et al. The thrombin inhibitor Argatroban reduces breast cancer malignancy and metastasis via osteopontin-dependent and osteopontin-independent mechanisms. Breast Cancer Res Treat. 2008;112:243–54. doi:10.1007/s10549-007-9865-4.CrossRefPubMedPubMedCentralGoogle Scholar
  34. Senger DR, Wirth DF, Hynes RO. Transformation-specific secreted phosophoproteins. Nature. 1980;286:619–21.PubMedPubMedCentralCrossRefGoogle Scholar
  35. Shevde LA, Samant RS. Role of osteopontin in the pathophysiology of cancer. Matrix Biol. 2014;37:131–41. doi:10.1016/j.matbio.2014.03.001.CrossRefPubMedPubMedCentralGoogle Scholar
  36. Shojaei F, Scott N, Kang X, Lappin PB, Fitzgerald AA, Karlicek S, et al. Osteopontin induces growth of metastatic tumors in a preclinical model of non-small lung cancer. J Exp Clin Cancer Res. 2012;31:26. doi:10.1186/1756-9966-31-26.CrossRefPubMedPubMedCentralGoogle Scholar
  37. Smith JH, Denhardt DT. Molecular cloning of a tumor promoter-inducible mRNA found in JB6 mouse epidermal cells: induction is stable at high, but not at low, cell densities. J Cell Biochem. 1987;34:13–22. doi:10.1002/jcb.240340103.CrossRefPubMedPubMedCentralGoogle Scholar
  38. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med: An Off Publ Am Assoc Oral Biologists. 2000;11:279–303.CrossRefGoogle Scholar
  39. Sun H, Zhu X, Lu PY, Rosato RR, Tan W, Zu Y. Oligonucleotide aptamers: new tools for targeted cancer therapy. Mol Ther: Nucleic Acids. 2014;3:e182. doi:10.1038/mtna.2014.32.CrossRefPubMedPubMedCentralGoogle Scholar
  40. Talbot LJ, Mi Z, Bhattacharya SD, Kim V, Guo H, Kuo PC. Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells. Surgery. 2011;150:224–30. doi:10.1016/j.surg.2011.05.015.CrossRefPubMedPubMedCentralGoogle Scholar
  41. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419. doi:10.1126/science.1260419.CrossRefPubMedPubMedCentralGoogle Scholar
  42. Wang D, Yamamoto S, Hijiya N, Benveniste EN, Gladson CL. Transcriptional regulation of the human osteopontin promoter: functional analysis and DNA-protein interactions. Oncogene. 2000;19:5801–9. doi:10.1038/sj.onc.1203917.CrossRefPubMedPubMedCentralGoogle Scholar
  43. Weber GF. The cancer biomarker osteopontin: combination with other markers. Cancer Genomics Proteomics. 2011;8:263–88.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Swapnil Bawage
    • 1
  • Shannon E. Weeks
    • 1
  • Lalita A. Shevde
    • 3
  • Rajeev S. Samant
    • 1
    • 2
  1. 1.Division of Molecular and Cellular Pathology, Department of PathologyUniversity of Alabama at Birmingham, Wallace Tumor InstituteBirminghamUSA
  2. 2.Department of Pathology and Comprehensive Cancer CenterThe University of AlabamaBirminghamUSA
  3. 3.Division of Molecular and Cellular Pathology, Department of Pathology and Comprehensive Cancer CenterUniversity of Alabama at Birmingham, Wallace Tumor InstituteBirminghamUSA